Year All2024202320222021 August 14, 2024 ArriVent BioPharma Reports Second Quarter 2024 Financial Results August 12, 2024 ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer June 5, 2024 ArriVent Announces a Multi-Target ADC Collaboration with Alphamab May 16, 2024 ArriVent Appoints John Hohneker, M.D., to its Board of Directors May 8, 2024 ArriVent BioPharma Reports First Quarter 2024 Financial Results April 22, 2024 ArriVent Appoints Kristine Peterson to its Board of Directors March 28, 2024 ArriVent BioPharma Reports Full Year 2023 Financial Results January 25, 2024 ArriVent Announces Pricing of Upsized Initial Public Offering January 5, 2024 ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer October 30, 2023 ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
August 12, 2024 ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
October 30, 2023 ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
